Biond Biologics Announces Poster Presentations at AACR 2020 Virtual AnnualMeeting
- SBIJI Innovation
- Aug 19, 2020
- 1 min read
July 9, 2020
Published work highlights the preclinical development of BND-22, an anti-ILT2 multi-cell checkpoint inhibitor that enhances the anti-tumor activity of innate and adaptive immune cells Also, first publication of a regulatory mechanism of the CD28/B7 immune stimulatory pathway, identifying CD28 shedding as a potential novel target for cancer therapeutics
Comentários